Trevi Therapeutics (NASDAQ: TRVI) reported Q1 EPS of ($0.06), $0.01 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.